Announcements Trials

Browse Landscape

Phase

Phase 2/3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 112 Lung Neoplasms 83 Lymphoma 76 Head and Neck Neoplasms 76 Glioblastoma 75 Squamous Cell Carcinoma of Head and Neck 71 Breast Neoplasms 71 Rectal Neoplasms 66 Esophageal Neoplasms 63 Prostatic Neoplasms 59 Leukemia 57 Central Nervous System Neoplasms 54 Pancreatic Neoplasms 51 Precursor Cell Lymphoblastic Leukemia-Lymphoma 47 Lymphoma, Non-Hodgkin 43 Lymphoma, Large B-Cell, Diffuse 43 Hodgkin Disease 42 Lymphoma, Follicular 41 Brain Neoplasms 40 Leukemia, Lymphocytic, Chronic, B-Cell 39 Esophageal Squamous Cell Carcinoma 39 Colorectal Neoplasms 38 Burkitt Lymphoma 37 Gliosarcoma 36 Lymphoma, Large-Cell, Immunoblastic 33 Uterine Cervical Neoplasms 31 Neoplasms 31 Adenocarcinoma Of Esophagus 31 Lymphoma, Mantle-Cell 30 Lymphoma, B-Cell, Marginal Zone 29

Interventions

triethanolamine 1 calcipotriene 1 Triamcinolone Acetonide 1 Radiotherapy, Conformal 1 Radiotherapy 1 Melatonin 1 Dimethyl Sulfoxide 1 Curcumin 1 Biafine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Radiodermatitis × Radiotherapy × Clear all

NCT07192588 2025-09-25

GuARD

Graegis Pharmaceuticals Ltd

Phase 2 Active not recruiting

Breast Neoplasms, Radiodermatitis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡